Trial · NCT03875638
Treating Hyperexcitability in AD With Levetiracetam
NCT03875638, Phase 2, Completed, Beth Israel Deaconess Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treating Hyperexcitability in AD With Levetiracetam. Trials, record NCT03875638. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03875638
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treating Hyperexcitability in AD With Levetiracetam
- NCT number
- NCT03875638
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 58 participants, actual
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
- Interventions
- Levetiracetam, Placebo oral capsule
- First posted
- 2019-03-15
- Last updated
- 2026-04-07
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neuropsychological Test Battery (NTB) | From enrollment until the end of the treatment periods at 5 months | Our primary cognitive outcome measure will be the mean z-score change relative to baseline on the NTB |
| Primary | Transcranial magnetic stimulation (TMS) resting motor threshold | From enrollment until the end of the treatment periods at 5 months | Our primary TMS electrophysiological outcome measure of cerebral cortical excitability will be the change in the TMS resting input-output curve inflection point |
| Primary | Transcranial magnetic stimulation (TMS)-evoked electroencephalogram (EEG) hypersynchrony | From enrollment until the end of the treatment periods at 5 months | Our primary electrophysiological measure of cerebral network excitability will be TMS-evoked EEG hypersynchrony with stimulation of parietal cortex |
| Primary | Resting-state electroencephalogram (EEG) beta band power | From enrollment until the end of the treatment periods at 5 months | Our primary electrophysiological measure of local network function will be resting-state EEG power in the beta band |
| Primary | Resting-state electroencephalogram (EEG) beta band connectivity | From enrollment until the end of the treatment periods at 5 months | Our primary electrophysiological measure of brain network interactions will be resting-state EEG functional connectivity in the beta band |
| Primary | Default-mode network resting-state functional magnetic resonance imaging (fMRI) functional connectivity | From enrollment until the end of the treatment periods at 5 months | Our primary imaging measure of integrity of macroscopic brain networks will be mean resting-state fMRI functional connectivity within the default-mode network |
| Primary | Change in motor evoked potential (MEP) amplitude | From enrollment until the end of the treatment periods at 5 months | Our primary transcranial magnetic stimulation (TMS) measure of plasticity in cortical excitability will be the change in MEP amplitude 10 minutes after intermittent theta-burst stimulation |
| Primary | Change in beta power after theta-burst stimulation | From enrollment until the end of the treatment periods at 5 months | Our primary transcranial magnetic stimulation (TMS) measure of plasticity in cortical oscillations will be change in resting-state electroencephalogram (EEG) beta power after theta-burst stimulation |
| Other | Transcranial magnetic stimulation (TMS)-evoked N45 electroencephalogram (EEG) potential | From enrollment until the end of the treatment periods at 5 months | The change in the N45 component of the TMS-evoked EEG potential with motor cortex stimulation, will serve as a measure of target engagement with levetiracetam therapy, and as a covariate in subsequent analyses. |
| Other | Interictal Epileptiform Discharges | Baseline | The presence or absence of interictal epileptiform discharges on the baseline ambulatory 24-hour EEG or the baseline high-density EEG will be used a primary baseline measure of cortical hyperexcitability |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03875638
GET https://conductscience.org/api/trials/v1/NCT03875638/registered